Clinical Trials Logo

Metastatic Esophageal Cancer clinical trials

View clinical trials related to Metastatic Esophageal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06251973 Recruiting - Clinical trials for Metastatic Gastric Cancer

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.

NCT ID: NCT06250036 Not yet recruiting - Clinical trials for Metastatic Gastric Cancer

Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)

ZODIAC
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)

NCT ID: NCT04166721 Recruiting - Clinical trials for Metastatic Gastric Cancer

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Start date: February 11, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who have progressed following chemotherapy.

NCT ID: NCT02843581 Completed - Clinical trials for Metastatic Esophageal Cancer

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer

Start date: July 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.

NCT ID: NCT02545751 Recruiting - Esophageal Cancer Clinical Trials

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

Start date: January 2016
Phase: Phase 2
Study type: Interventional

Patients with esophageal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response after Stereotactic Body Radiation Therapy(SBRT) of a metastatic site in metastatic esophageal cancer patients. 2. To induce the efficacy (effectiveness) of a new combination of therapy, SBRT and thymalfasin for heavily pretreated, metastatic esophageal cancer patients; This study will help find out what effects (good or bad) the combination of radiotherapy and thymalfasin has on metastatic esophageal cancer.

NCT ID: NCT02544737 Recruiting - Esophageal Cancer Clinical Trials

Apatinib for Metastatic Esophageal Cancer.

Start date: September 2015
Phase: Phase 2
Study type: Interventional

Patients with esophageal cancer that had metastatic lesions after been treated with surgery or definitive chemoradiotherapy are being asked to participate in this study. Apatinib is a small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib. The purpose of this study is to determine what effects apatinib has on metastatic esophageal cancer. These effects include whether apatinib could shrink the tumor or slow down its growth and what side effects apatinib will have on the tumor.

NCT ID: NCT01715233 Completed - Gastric Cancer Clinical Trials

Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.

Start date: December 2012
Phase: Phase 2
Study type: Interventional

To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.